Stifel initiated coverage on Avalo Therapeutics with a new price target
$AVTX
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $36.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/9/2026 | $48.00 | Outperform | Wolfe Research |
| 4/6/2026 | $52.00 | Mkt Outperform | Citizens |
| 2/2/2026 | $50.00 | Buy | Guggenheim |
| 12/18/2025 | $39.00 | Outperform | Mizuho |
| 9/17/2025 | $15.00 → $25.00 | Buy | H.C. Wainwright |
| 9/5/2025 | Buy | TD Cowen | |
| 8/15/2025 | Overweight | Cantor Fitzgerald | |
| 6/2/2025 | $15.00 | Buy | H.C. Wainwright |
SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
Wolfe Research initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $48.00
Citizens initiated coverage of Avalo Therapeutics with a rating of Mkt Outperform and set a new price target of $52.00
Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00
WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company granted an inducement award consisting of an option to purchase 34,000 shares of its common stock to one new employee (the "Option"). The award was approved by the Compensation Committee of the Board of Directors as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Option was granted on May 21, 2026 and has an exercise price of $16.60 per share, which is e
Achieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 programCompleted public offering of equity securities for gross proceeds of $431.3 million Cash, cash equivalents, and short-term investments of $82 million as of March 31, 2026, not including the subsequent financing WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and first quarter 2026 financial results.
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) ("Avalo"), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated inflammatory diseases, today announced the pricing of its underwritten public offering of 19,730,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,400,000 shares of common stock. The shares of common stock are being sold at a public offering price of $17.75 per share and the pre-funded warrants are being sold at a public offering price of $17.749 per pre-funded warrant, which represents the per share public offering price of
WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei
WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit. "Kevin joins Avalo at an exciting time, as we continue to advance AVTX-009 through the Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with topline data expected mid next year," said
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. "We are pleased to welcome Dr. Jain to Avalo's Board of Directors," said Michael Heffernan, Chairman of the Board. "Rita's extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1β monoclonal antibody in a Phase 2 trial for hidradenitis suppurativa (HS) and take a thought
SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)